Pharmaceutical giant AstraZeneca has legally acknowledged for the first time that its COVID-19 vaccine, under the global brand names Covishield and Vaxzevria, could trigger a rare adverse health condition.The vaccine producer stated in court documents that the inoculation could occasionally induce Thrombosis with Thrombocytopenia Syndrome (TTS), a disorder resulting in blood clots and a reduced platelet count, as reported in The Telegraph. A class action lawsuit, on account of allegations that... Read this story
